Experts examine the importance of fibrosis staging in the risk assessment and management of metabolic-associated steatohepatitis (MASH). The session explores the clinical implications of focusing on early-stage versus late-stage fibrosis; evaluates the role of advanced diagnostic tools in stratifying risk; and reviews how targeted approaches can improve patient outcomes. This community conversation aims to impart a deeper understanding of how to prioritize interventions based on fibrosis severity and emerging evidence.